Biotech company Aviceda Therapeutics has announced the formation of an Executive Team to help to guide its development of breakthrough therapeutics and continue its growth as a business. The Executive Leadership Team will be led by company co-founder Mohamed Genead, as CEO and Chairman, and comprise fellow co-founders Derek Kunimoto, Michael Tolentino and Christopher Scott, as well as David Callanan.
“Aviceda is extremely proud of the world-class team of internationally renowned experts we have assembled to guide the company in the next phases of growth,” said Dr. Genead. “In addition to offering keen scientific insight into product development, each member of the Executive Team also brings with them previous experience in key leadership positions in the pharmaceutical industry. Being able to tap into this knowledge base will undoubtedly pay huge dividends as Aviceda pursues an aggressive but realistic growth and product development strategy.”
Dr. Genead is a board-certified ophthalmologist and retina specialist with more than 20 years of experience in pharmaceutical drug and business development. He co-founded Aviceda in 2018, having been Chief Medical Officer and Executive Vice-President for GenSight Biologics before that.
Dr. Callanan is a board-certified ophthalmologist, a clinical Professor at the University of Texas Southwestern Medical School in Dallas, Texas, and a surgeon for Texas Retina Associates. A widely respected leader and specialist, he was a Heed Ophthalmic Foundation Fellow at the prestigious Bascom Palmer Eye Institute in Miami, and has received a National Research Service Award from the National Institutes of Health for his research in the field. He joins Aviceda as Chief Medical Officer.
Dr. Kunimoto is a former Rhodes Scholar with a medical degree with honors from Harvard Medical School and a law degree with honors from Oxford University. He has been COO of Aviceda Therapeutics since co-founding the company, and has also been a managing partner of Retinal Consultants of Arizona.
Dr. Tolentino is also a co-founder of Aviceda, and serves as the company’s Chief Technology Officer. He co-founded and served as the interim CEO/CSO for Acuity Pharmaceuticals, has been the principal instigator of more than 150 clinical trials, and has authored more than 100 publications.
Professor Scott is Aviceda’s Scientific Co-Founder, and serves as Chief Science Officer. He is globally renowned for his work developing novel approaches in the field of antibody and nanomedicine-based therapies for the treatment of cancer and other conditions. He is also the Director of the Patrick G Johnston Centre for Cancer Research and Cell Biology at Queen’s University Belfast.